Table 5 Series of patients with recurrent gliomas treated with radio-chemotherapy.
From: Radiotherapeutic alternatives for previously irradiated recurrent gliomas
Author | RT-Technique | Chemotherapy | Pt. Number | Histology | Tumor size (ml; median) | Median Dose (Gy) | Median Fraction Size (Gy) | Median survival (months) | Rate of Severe Toxiticy/Reoperation rate (%) |
|---|---|---|---|---|---|---|---|---|---|
Arcicasa et al., 1999 | CH-EBRT | CCNU | 24 (7) | GBM (AA) | - | 34.5 | 1.5 | 13.7 | - |
Glass et al., 1997 | CH-HSFRT | Cisplatin | 13 (7) | GBM (AA) | 14 | 35–42 (range) | 3.5–6 (range) | 13.7 | - |
Lederman et al., 2000 | CH-HSFRT | Paclitaxel | 88 | GBM | 32.7 | 18–36 (range) | 4–9 (range) | 7 | 11% |
Wurm et al., 2006 | CH-HSFRT | Topotecan | 5 (25) | III | 16.5 | 30 | 5 | 21.3 | - |
Wurm et al., 2006 | CH-HSFRT | Topotecan | 20 (25) | IV | 16.5 | 30 | 5 | 7.9 | Â |